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Introduction
Although renal cell carcinoma (RCC) can be detected
by flank pain and hematuria, the development of
imaging techniques such as ultrasonography and
computed tomography (CT) has led to an increased
detection rate of small renal tumors.1 Currently, almost
2-thirds of diagnosed renal cancers are incidental
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Background: Preliminary data regarding the use of percutaneous radiofrequency ablation (RFA) for the treatment
of renal cell carcinoma (RCC) are encouraging, and show the technique to be associated with minimal morbidity.
Thus, the current study was designed to evaluate the clinical applications, treatment efficacy, and complications
of percutaneous RFA in RCC.
Methods: From February 2003 to February 2004, 12 consecutive patients with histopathologically proven RCC
underwent imaging-guided percutaneous RFA. The mean age of the patients (8 men and 4 women) was 76 years
(range, 56–87 years), and mean tumor diameter was 3.7 cm (range, 2.2–8.0 cm). The efficacy of RFA was evaluated
with contrast-enhanced, dynamic computed tomography (CT) performed 1 month after treatment, and then every
3 months. A Radionics device with an internally cooled electrode was used in 7 patients, and a radiofrequency
interstitial tissue ablation (RITA) device with an expandable needle electrode was used in 5. Complete necrosis
was defined as a lack of contrast enhancement in the treated region on follow-up CT studies.
Results: Overall, 16 sessions of RFA were performed for 12 solitary renal tumors in 12 patients: 8 patients underwent
a single RFA session, whereas 4 had 2 sessions. Dynamic CT after RFA showed complete necrosis in 9 of 12 tumors.
In 3 patients with tumors of 4.5–8.0 cm in diameter, enhancement of residual tissue was observed after RFA treatment,
thus indicating residual tumor. Complete tumor necrosis was seen in all 5 tumors (100%) of diameter ) 3.0 cm;
3 of 4 tumors (75%) of diameter 3.1–5.0 cm; and 1 of 3 tumors (33%) of diameter > 5.0 cm. A big subcapsular
hematoma, which was found in 1 patient after RFA, resolved completely within 10 months without treatment; no
serious complications occurred in the other 11 patients.
Conclusion: Percutaneous RFA is effective in the treatment of RCC. It is most successful for tumors not larger
than 3 cm in diameter, and has a satisfactory success rate in tumors of 3–5 cm in diameter. The rate of serious
complications of RFA is low. Further studies are necessary to determine the long-term efficacy of RFA in RCC.
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findings in asymptomatic patients.2 The traditional
treatment for renal tumors is radical or partial
nephrectomy,3,4 and although laparoscopic
nephrectomy is less invasive than traditional open
nephrectomy,5 all these procedures require hospital
admission, general anesthesia and operation, along
with the attendant risks and costs. For patients who are
not candidates for surgery, or for those who refuse
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surgery, minimally invasive thermal ablation techniques
are a promising option. Although percutaneous
radiofrequency ablation (RFA) for the treatment of
RCC is a recent innovation, results from preliminary
clinical series and animal studies are encouraging,6–11
and show RCC to be technically feasible and to have
minimal morbidity.12–23
In this study, we describe our experience of using
percutaneous imaging-guided RFA in 12 patients with
RCC and review the treatment’s techniques, efficacy,
and complications; to the best of our knowledge, no
such study has yet been reported in Taiwan.
Methods
Study participants
From February 2003 to February 2004, 12 consecutive
patients (8 men and 4 women; mean age, 76 years; age
range, 56–87 years) who underwent percutaneous
imaging-guided RFA for the treatment of RCC were
evaluated for clinical outcome. This prospective study
was approved by our institutional review board, and
informed consent was obtained from all patients before
the procedure. The study participants either refused
surgery (n = 4), or were not considered surgical candi-
dates because of advanced age, comorbid conditions
(5), or the presence of a solitary kidney (3).
All patients had their diagnosis confirmed by
imaging-guided biopsy, performed either in advance
or simultaneously with RFA. Biopsy results revealed
RCC in all cases. Tumor size ranged from 2.2–8.0 cm
(mean, 3.7 cm), with tumors classified into 3 groups
depending on their diameter: 5 were ) 3 cm; 4 were
3.1–5.0 cm; and 3 were > 5 cm.
Radiofrequency tumor ablation technique
All patients were interviewed before the treatment by
an experienced interventional radiologist, and were
assessed with ultrasonography before the procedure
to determine whether the tumor was amenable to
ablation under ultrasound guidance. If the lesion was
suboptimally visualized using ultrasonography, RFA
was performed with CT guidance. Ablations were
performed with ultrasonography in 8 patients and CT
in 4. RFA was performed in 9 patients with meperi-
dine and in 3 with conscious sedation (droperidol,
midazolam, fentanyl) administered and monitored by
anesthesiologists.
Two different RFA devices were used as described
previously:24,25 a radiofrequency interstitial tissue
ablation (RITA) device (Rita Medical Systems,
Mountain View, CA, USA), and a Radionics device
(Radionics, Burlington, MA, USA). With the RITA
device, ablation was performed with an expandable
needle electrode (StarburstTM, 2–3 cm; or StarburstTM
XL, 3–5 cm). With the Radionics device, treatment
was performed with either a cluster (3-prong, 2.5-cm
active tip) or a single (2- or 3-cm active tip) needle
electrode, depending on tumor size. Each tumor had
1–5 ablations per session, with the number depending
on tumor size.
Imaging assessment after ablation
After RFA, all patients underwent immediate follow-
up ultrasonography or contrast-enhanced dynamic
CT to evaluate the possibility of bleeding or fluid
accumulation. The efficacy of RFA was evaluated by
contrast-enhanced, dynamic CT performed 1 month
after RFA, and then every 3 months. Treated tumors
were assessed for residual enhancement and size
changes. Complete necrosis was defined as a lack of
contrast enhancement in the treated region on follow-
up CT studies, and all follow-up images were also
assessed for the development of new metastatic disease
and ancillary peritumoral changes. Residual disease
was defined as persistent enhancement in an area or
areas of tumor after ablation, as determined at the
1-month follow-up study. Recurrent disease was
defined as new tumor enhancement, after at least 1
imaging study had demonstrated complete eradication
of enhancement. Assessment of images was performed
in consensus by 2 experienced radiologists.
Results
There were 16 sessions of RFA for 12 solid renal
tumors in 12 patients: 8 patients had a single RFA
session, and the other 4 had 2 sessions. Nine tumors
were located in the right kidney and 3 in the left
kidney. Five patients were treated with the RITA
device, and 7 with the Radionics device. Of patients
treated with the RITA system, 3 were treated with
2–3 cm active electrodes, and 2 with 3–5 cm active
electrodes. Of the 7 patients treated with the Radionics
system, 2 were treated with a 2-cm active-tip electrode,
4 with a 3-cm active-tip electrode, and 1 with a 2.5-cm
cluster electrode.
The mean duration of follow-up was 14 months
(range, 8–20 months). Post-treatment CT showed
total necrosis in 8 of 12 tumors (67%) after 1 session
of RFA treatment (Figure 1), and in 9 of 12 tumors
(75%) after 2 sessions. Residual tumor was observed
in 3 patients with tumors of 4.5–8.0 cm in diameter.
Complete necrosis was seen in all small tumors
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(diameter ) 3.0 cm), 3 of 4 medium tumors (3.1–5.0
cm), and 1 of 3 large tumors (> 5.0 cm). No recurrent
tumor was found in the 9 tumors with complete
necrosis.
All patients tolerated RFA with no major com-
plications. After the procedure, 1 patient developed a
big subcapsular hematoma, but this resolved completely
in 10 months without treatment (Figure 2), and 3
patients had pain or paresthesia around the puncture
site for several days or weeks, but this resolved
spontaneously. All patients were discharged with a
prescription for pain medication (acetaminophen or
nonsteroidal anti-inflammatory drug), but only 1
patient required analgesia for more than 7 days after
RFA. No patients experienced the postablative
Figure 1. Computed tomography scans from an 84-year-old man
with biopsy-proven renal cell carcinoma of the right kidney: (A) a
scan before radiofrequency ablation (RFA) shows a 2.5-cm
enhanced soft tissue mass (arrowhead) in the anterior part of the
middle pole of the right kidney; (B) a scan 4 months after RFA
shows no enhancement of the mass (arrowhead), which had been
treated with percutaneous ultrasound-guided RFA.
syndrome (pain, fever, malaise, and elevated white
blood cell count) described after hepatic RFA, and no
patients had antibiotics before, during or after RFA.
Discussion
Percutaneous RFA has been used to ablate liver
neoplasms with good outcome.26 Radiofrequency
thermal ablation works by converting radiofrequency
waves into heat through ionic vibration. Alternating
current passing from an electrode into the surrounding
tissue causes ions to vibrate in an attempt to follow the
directional current change. Thus, ionic friction generates
heat in the tissue and not in the electrode itself. Increased
current leads to more vigorous ionic motion and
increased temperature over a period of time, eventually
leading to coagulation necrosis and cell death. The
purpose of RFA is to achieve local temperatures that are
lethal to the targeted tissue. Generally, thermal damage
to cells begins at 42$C; once above 60$C, intracellular
proteins are denatured, the lipid layer melts, and
irreversible cell death occurs.27
The traditional treatment for localized RCC is
open, partial or radical nephrectomy,28 but this is not
ideal for all tumors because some patients are unable
or unwilling to undergo surgery, or would have
insufficient functional renal tissue remaining after
such intervention.24 Attention has recently focused on
RFA as a minimally invasive option for RCC: various
outcomes have been reported,14–19 and the duration of
hospital stay, costs, and risk of complications tend to
be less for RFA than nephrectomy.
The success rate of RFA in treating RCC depends
mainly on tumor size.15,17,18 In our study, no small
tumors had residual or recurrent tumor during follow-
up CT scans. However, after a single session of RFA,
residual tumor was found in all 3 patients with larger
tumors (4.5–8.0 cm in diameter), and was still evident
in 2 patients after the second session of RFA. These
findings suggest that larger tumors are more difficult
to eradicate completely with RFA. The presence of
residual disease detected on follow-up scans does not
necessarily indicate a poor outcome, because residual
tumor can be re-treated and there appears to be no
higher risk of systemic spread from foci of residual
tumor. No patients in our series, or in other published
series, developed detectable metastatic disease after
incomplete renal tumor ablation.15–19
Other factors that may affect the success rate of
RFA are tumor location and the surrounding tissue.
Centrally located tumors are more difficult to treat
successfully because of heat loss due to the large
A
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amount of vascularity in the central kidney. During
RFA, heat loss occurs at the needle tip, mainly through
convection by blood circulation.15,29,30 Exophytic
tumors, which are partially surrounded by avascular,
perirenal fat, are easy to completely eradicate with
RFA. Surrounding fibrosis, as seen in chronic renal
disease,17 is also expected to reduce thermal conduc-
tion and heat dissipation, thus improving the efficacy
of RFA.
The rate of serious complications with RFA is low.
Indeed, a major advantage of RFA is the ability to
avoid tract bleeding and tumor seeding by coagulating
the tract when the ablating electrode is withdrawn.
Some studies have shown that RFA for RCC has a low
complication rate (approximately 7–17%),15,24 and our
study identified a serious complication in only 1 of 12
patients (8%): a large subcapsular hematoma, which,
nonetheless, was completely resolved without treatment
10 months after RFA. For several days or weeks after
RFA in our study, 3 patients had local pain or paresthesia
around the puncture wound, but these events resolved
spontaneously, presumably because of only transient
damage to intercostal or lumbar nerves in the affected
dermatome. Other complications of RFA reported in
the literature include infection, ureteral obstruction,
and fistula, which can all be treated conservatively.16
One limitation of our study was that RFA outcomes
were judged by contrast enhancement during follow-
up CT studies.31 Lack of such enhancement has
generally been assumed to indicate a lack of viable
tumor. Jacomides et al32 performed tumor resection,
secondary to RFA, in 5 of 17 laparoscopically treated
RCC patients and found no residual tumor on histolog-
ic study. Matlaga et al33 also found uniform tumor de-
vitalization without viable tumor. In our experience,
it is crucial to choose a suitable ablation protocol and
RFA electrode to create necrosis large enough to pro-
vide an adequate safety margin. We believe that a lack
of contrast enhancement on CT indicates complete
tumor eradication, but follow-up surveillance imaging
is warranted because long-term results for renal tumor
RFA are lacking; such follow-up scans should be used
to detect local or metastatic lesions.
In conclusion, percutaneous imaging-guided RFA
is a technique with rapidly increasing usefulness. It
allows the safe and accurate treatment of renal tumors
and, as a minimally invasive and nephron-sparing
procedure, it is ideal for patients who are not good
surgical candidates. The success of RFA for RCC is
influenced primarily by tumor size. Indeed, RFA is a
very promising technique that is most successful for
tumors ) 3 cm in diameter, with satisfactory success
against tumors 3.1–5.0 cm in diameter. Long-term
follow-up data are still needed regarding local and
systemic recurrence and survival after RFA, and will
provide additional guidance in the initial selection of
patients for this treatment.
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